Compare ZTS & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTS | IQV |
|---|---|---|
| Founded | 1952 | 1982 |
| Country | United States | United States |
| Employees | 14500 | 93000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2B | 28.6B |
| IPO Year | 2012 | 2013 |
| Metric | ZTS | IQV |
|---|---|---|
| Price | $74.21 | $171.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $154.18 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 6.8M | 1.6M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | ★ 10.05 | 4.67 |
| EPS | 1.42 | ★ 1.61 |
| Revenue | $9,467,000,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $5.63 | $6.77 |
| Revenue Next Year | $4.77 | $5.89 |
| P/E Ratio | ★ $52.94 | $106.17 |
| Revenue Growth | 2.28 | ★ 41.60 |
| 52 Week Low | $73.98 | $134.65 |
| 52 Week High | $172.23 | $247.05 |
| Indicator | ZTS | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 13.81 | 51.09 |
| Support Level | N/A | $159.08 |
| Resistance Level | $129.32 | $172.80 |
| Average True Range (ATR) | 3.46 | 6.75 |
| MACD | -3.83 | 0.68 |
| Stochastic Oscillator | 0.40 | 60.50 |
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.